Wildes Tanya M
University of Nebraska Medical Center/Nebraska Medicine, Omaha, Nebraska, USA.
Br J Haematol. 2025 May;206(5):1523-1525. doi: 10.1111/bjh.20000. Epub 2025 Jan 27.
Treatment options for older adults with relapsed multiple myeloma are constrained by the toxicities of existing treatments, the ageing-associated vulnerabilities that may increase the risk of poor treatment tolerance and patient preferences for treatments that do not impair their function or cognition. The study by Toussea et al. epitomizes approaches to designing trials specifically for more vulnerable older adults and moves the field forward with a regimen of great interest for older adults experiencing their first relapse. Commentary on: Touzeau et al. Iberdomide, Ixazomib and Dexamethasone in elderly patients with multiple myeloma at first relapse. Br J Haematol 2025; 206:1366-1372.
复发多发性骨髓瘤老年患者的治疗选择受到现有治疗毒性的限制，与衰老相关的脆弱性可能会增加治疗耐受性差的风险，以及患者对不损害其功能或认知的治疗的偏好。图塞等人的研究体现了专门为更脆弱的老年人设计试验的方法，并以一种对首次复发的老年人极具吸引力的治疗方案推动了该领域的发展。评论文章：图佐等人。伊布多米德、伊沙佐米和地塞米松用于首次复发的老年多发性骨髓瘤患者。《英国血液学杂志》2025年；206:1366 - 1372。
